Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Common Equity: 2011-2024

Historic Common Equity for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to $46.1 million.

  • Niagen Bioscience's Common Equity rose 105.64% to $70.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.7 million, marking a year-over-year increase of 105.64%. This contributed to the annual value of $46.1 million for FY2024, which is 61.98% up from last year.
  • Niagen Bioscience's Common Equity amounted to $46.1 million in FY2024, which was up 61.98% from $28.5 million recorded in FY2023.
  • In the past 5 years, Niagen Bioscience's Common Equity ranged from a high of $46.1 million in FY2024 and a low of $16.4 million during FY2020.
  • In the last 3 years, Niagen Bioscience's Common Equity had a median value of $28.7 million in 2022 and averaged $34.4 million.
  • As far as peak fluctuations go, Niagen Bioscience's Common Equity dropped by 19.67% in 2020, and later spiked by 93.17% in 2021.
  • Niagen Bioscience's Common Equity (Yearly) stood at $16.4 million in 2020, then soared by 93.17% to $31.7 million in 2021, then fell by 9.63% to $28.7 million in 2022, then dropped by 0.75% to $28.5 million in 2023, then skyrocketed by 61.98% to $46.1 million in 2024.